证券代码：300138 证券简称：晨光生物 公告编号：2023—109 晨光生物科技集团股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）于 2022 年 9 月 22 日召开的第四届董事会第四十五次会议审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》。同意公司在不影响募集资金投资项目建设的前提下，使 用不超过 2.75 亿元暂时闲置募集资金进行现金管理，用于购买安全性高、流动 性好的理财产品/结构性存款产品等，期限为自董事会审议通过之日起不超过 12 个月，期限内在上述资金额度范围内滚动使用，到期前将归还至公司募集资金专 户。公司独立董事、监事会、保荐机构已发表明确同意意见，详细内容请见 2022 年 9 月 22 日披露于巨潮资讯网的《关于使用部分闲置募集资金进行现金管理的 公告》及相关公告文件。 前期，公司使用暂时闲置募集资金 3,000 万元购买了江海证券有限公司收益 凭证（详细内容请见 2022 年 11 月 10 日披露于巨潮资讯网 ...

一、保荐机构进行的核查工作 报告期内，本保荐机构对晨光生物募集资金的存放、使用及募集资金投资项 目实施情况进行了核查，主要内容包括：与公司相关董事、监事、高级管理人员、 内部审计人员、注册会计师等人员交谈，查询了募集资金专户银行对账单，半年 度募集资金存放与使用情况的专项报告以及各项业务和管理规章制度，查阅募集 资金使用凭证，从公司募集资金的日常管理、使用用途、信息披露等方面对其募 集资金制度的完整性、合理性及有效性进行核查。 二、募集资金基本情况 经中国证券监督管理委员会《关于核准晨光生物科技集团股份有限公司公开 发行可转换公司债券的批复》（证监许可[2019]2571号）核准，同意晨光生物向 社会公开发行面值总额63,000万元的可转换公司债券，期限6年。本次发行可转 换公司债券的募集资金总额为人民币63,000万元，扣除发行费用1,095.57万元后， 晨光生物实际募集资金净额为61,904.43万元。上述募集资金于2020年6月23日到 位，已由中审众环会计师事务所审验并出具众环验字[2020]第020023号《验资报 告》。 中原证券股份有限公司 关于晨光生物科技集团股份有限公司 2023 年半年度 ...

控股股东及其他关联方非经营性资金占用及清偿情况表(2023年上半年度） 单位：晨光生物科技集团股份有限公司 | 控股股东或其他 | 占用时间 | 发生原因 | 期初余额 | 报告期新增 | 报告期偿还 | 期末余额 | 截至半年报 | 预计 | 预计 | 预计 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 关联方名称 | | | | 占用金额 | 总金额 | | 披露日余额 | 偿还方式 | 偿还金额 | 偿还时间 | | | | 河北晨华共两名股东，分别为晨光生物、华 裕永诚。为支持河北晨华业务发展，河北晨 | | | | | | | | 2023年4月完成 | | 河北晨华农业科 | | 华的两名股东决定按持股比例、同等条件分 | | | | | | | | 借款本金偿 | | 技有限公司 | 本报告期 | 别向其提供不超过3,000万元的资金支持，期 | 2,536.25 - - | 29.59 | 2,565.84 | | | 现金清偿 | - | 还，5月完成剩 | | | | 限为自签订的协议生效之日 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥3,668,696,988.23, representing a 13.68% increase compared to ¥3,227,191,537.69 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥298,654,394.22, an increase of 24.23% from ¥240,397,801.18 year-on-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥235,787,929.76, up 11.49% from ¥211,485,971.37 in the previous year[22]. - The basic earnings per share increased to ¥0.56, a rise of 24.44% compared to ¥0.45 in the same period last year[22]. - The total assets at the end of the reporting period were ¥7,239,852,514.36, reflecting a 4.57% increase from ¥6,923,739,569.28 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were ¥3,397,025,349.56, which is a 7.34% increase from ¥3,164,817,273.47 at the end of the previous year[22]. - The net cash flow from operating activities was ¥682,564,463.95, down 29.19% from ¥963,901,233.43 in the same period last year[22]. - The weighted average return on net assets was 9.02%, an increase of 0.73% from 8.29% in the previous year[22]. - The company achieved a revenue of 3.669 billion yuan in the first half of 2023, representing a year-on-year growth of 13.68%[44]. - The net profit attributable to shareholders reached 299 million yuan, an increase of 24.23% compared to the previous year[44]. Market and Industry Insights - The global market for plant extracts is projected to reach USD 59.4 billion by 2025, indicating significant growth potential in the industry[31]. - The plant extraction industry in China has over 2,000 companies, with a trend towards consolidation and a focus on quality and technology-driven competition[34]. - The natural plant extract industry is driven by the long-term trend of replacing synthetic products, with applications in food, medicine, and cosmetics, indicating a broad market outlook[36]. - The global natural food coloring market is expected to reach $2.5 billion by 2025, driven by safety concerns over synthetic colors[37]. - The compound seasoning market in China grew from 43.2 billion yuan in 2011 to 144 billion yuan in 2020, with a CAGR of 14.31%[37]. - The penetration rate of pepper extract in the restaurant industry is currently below 2%, indicating significant growth potential[39]. - The demand for natural sweeteners is increasing as consumers shift towards low-sugar and no-sugar consumption concepts, with steviol glycosides being a key natural sweetener[40]. - Natural plant extracts are becoming essential raw materials in pharmaceuticals, health products, and cosmetics, with a positive development outlook[40]. Product Development and R&D - The company employs a market-oriented R&D model that includes stages from small trials to industrial production, ensuring alignment with market needs[34]. - The company has developed over 100 varieties across six major series, including natural pigments and health food products[43]. - The company has invested significantly in R&D, focusing on process technology improvements and new product development[42]. - The company is currently developing a new process for pepper extract with a focus on low cost and high yield, and is in the process of scaling up the new technology[48]. - The company is working on the development of microencapsulated products to broaden its product range, with ongoing pilot tests and production trials[48]. - The company has achieved breakthroughs in the extraction of flavonoids from locust tree seeds, improving the efficiency of rutin acquisition and addressing traditional water consumption issues[49]. - The company has completed the verification of raw materials from different origins for locust tree seed products, enabling the production transformation of solvent extraction technology[49]. - The company has launched several new products, including various health supplements and soft capsules, to diversify its offerings[50]. Strategic Goals and Expansion - The company emphasizes the importance of global resource allocation to achieve its strategic goal of building a world-class natural extract industry base[3]. - The company is actively expanding its raw material bases, with significant growth in planting areas in India and Zambia[46]. - Morning Glory Bio has become the largest listed company in the domestic plant extract industry, ranking among the top tier globally, aiming to surpass foreign leaders like Frutarom and Kalsec[35]. - The company aims to establish around ten world-leading products in the near future[44]. - The company is expanding its operations internationally, with factories being established in India and Zambia as part of the Belt and Road Initiative[145]. Environmental and Social Responsibility - The company is committed to addressing environmental concerns through innovative extraction processes in its product development[49]. - The company has established a comprehensive wastewater treatment system to manage chemical pollutants effectively[142]. - The company has reported a significant investment in environmental protection equipment, including dust collectors and odor removal towers, to comply with environmental regulations[145]. - The company has actively participated in social welfare activities, contributing approximately 1 million rupees to local public services in India[146]. - The company has implemented measures to control emissions of nitrogen oxides, with a maximum allowable concentration of ≤80 mg/m³[139]. Corporate Governance and Shareholder Engagement - The company held an annual general meeting on April 19, 2023, with 31.52% of investors participating, approving various proposals including the 2022 annual report and financial statements[130]. - The company conducted investor communications through various platforms, including a conference call on March 28, 2023, attended by 210 investors[127]. - The company is focused on maintaining transparency and engaging with investors through regular updates and meetings[127]. - The company has not reported any significant mergers or acquisitions during the reporting period[132]. - The company confirmed that all commitments made by major shareholders have been fulfilled as of the report date[150]. Risk Management - The company has identified several risks associated with derivative investments, including market risk, basis risk, liquidity risk, operational risk, technical risk, and policy risk[114]. - The company has established a risk control framework to manage and mitigate the identified risks effectively[114]. - The company is monitoring foreign exchange risks as international revenues grow, utilizing financial tools to mitigate potential impacts[125]. Related Party Transactions - The company engaged in related party transactions, with a total transaction amount of 28.65 million yuan, accounting for 12.83% of similar transactions[165]. - The company confirmed that all related party transactions have not exceeded the approved limits as of the reporting period[168]. Financial Support and Guarantees - The company provided financial support of up to 30 million yuan to Hebei Chenhua, with a repayment period not exceeding 12 months, approved in the 2021 annual general meeting[155]. - The total approved guarantee amount for subsidiaries during the reporting period is CNY 310 million, with actual guarantees amounting to CNY 66.424 million[185]. - The company has no guarantees provided for shareholders, actual controllers, or their related parties[186].

上市公司2023年上半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：晨光生物科技集团股份有限公司 金额单位：人民币万元 | | | 占用方与上市公司的关联 | 上市公司核算的 | 2023年初占用 | 2023年上半年度占 | 2023年上半年度占 | 2023年上半年度偿 | 2023年6月末占 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 关系 | 会计科目 | 资金余额 | 用累计发生金额（不 | 用资金的利息（如 | 还累计发生额 | 用资金余额 | 占用形成原因 | 占用性质 | | | | | | | 含利息） | 有） | | | | | | 控股股东、实际控制人及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 小 计 | —— | —— | —— | - | - | - | - | - | —— | —— | | 前控股股东、实际控制人 | | | | | | | | | ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—104 晨光生物科技集团股份有限公司 第五届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、 审议通过了《关于<募集资金 2023 年半年度存放与使用情况的专项报告> 的议案》 表决结果：同意六票；反对零票；弃权零票。 报告具体内容、独立董事、监事会、保荐机构发表的意见，详见巨潮资讯网同 期披露的相关文件。 特此公告 晨光生物科技集团股份有限公司 董事会 2023 年 8 月 11 日 晨光生物科技集团股份有限公司（以下简称"公司"）董事会于 2023 年 7 月 27 日以专人送达、邮件方式向全体董事发出第五届董事会第二次会议通知，会议于 2023 年 8 月 10 日在公司会议室以现场与通讯相结合的方式召开。本次会议由董事长卢庆 国先生主持，应出席会议董事六人，实际出席会议董事六人（独立董事戴小枫、牛 翃、厉梁秋，董事卢颖以通讯表决方式参加），公司监事、高级管理人员列席了本 次会议。本次会议召开符合《公司法》《公司章程》等有关规定。经与会董事研究、 讨论，审议通过 ...

晨光生物科技集团股份有限公司 独立董事关于公司2023年半年度相关事项的独立意见 根据《公司法》《证券法》《上市公司独立董事规则》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板 上市公司规范运作》等法律法规及《公司章程》的有关规定，作为晨光生物科技 集团股份有限公司（简称"公司"或"晨光生物"）的独立董事，本着谨慎原则， 基于独立判断的立场，现发表独立意见如下： 一、关于公司 2023 年半年度关联交易事项的独立意见 报告期内，公司独立董事根据股东大会审批的标准领取工作津贴，其他董事、 监事、高管根据其在公司担任的运营职务领取薪酬（不领取董事或监事津贴）， 决策程序合规。2023 年上半年公司与关联方发生的关联交易均根据《深圳证券 交易所创业板股票上市规则》《公司章程》等相关规定履行了相关审批程序，交 易金额未超过经审批的关联交易额度，交易的价格按照独立交易原则，参考市场 行情协商确定，不会损害公司及股东利益，不影响公司的独立性。 二、关于公司控股股东及其他关联方占用公司资金、公司对外担保情况的独 立意见 三、关于募集资金 2023 年半年度存放与使用情况的独立意见 ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—108 晨光生物科技集团股份有限公司董事会 关于募集资金 2023 年半年度存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》等有关要求，公司董事会编制了截至 2023 年 6 月 30 日"关于募集资金 2023 年半年度存放与使用情况的专项报告"。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准晨光生物科技集团股份有限公司公开 发行可转换公司债券的批复》（证监许可[2019]2571 号）核准，同意公司向社会 公开发行面值总额 63,000 万元的可转换公司债券，期限 6 年。本次发行可转换 公司债券的募集资金总额为人民币 63,000 万元，扣除通过募集资金专户支付的 承销、保荐佣金共计人民币 10,698,113.20 元（不含税）后，主承销商中原证券 股份有限公司于 2020 年 6 月 23 日将款项 ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—105 晨光生物科技集团股份有限公司 第五届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）监事会于2023年7月 27日以专人送达、邮件方式向全体监事发出第五届监事会第二次会议通知，会议 于2023年8月10日在公司会议室以现场与通讯相结合的方式召开。本次会议由监 事会主席翟艳忠先生主持，应出席会议监事三人，实际出席会议监事三人（监事 王少华以通讯表决方式参加），本次会议召开符合《公司法》《公司章程》等有 关规定。经与会监事研究、讨论，审议通过以下议案： 一、 审议通过了《关于 2023 年半年度报告全文及其摘要的议案》 经审核，监事会认为：公司董事会编制和审核公司 2023 年半年度报告的程 序符合法律、法规、中国证监会和深圳证券交易所等相关规定，报告内容真实、 准确、完整地反映了公司的实际情况，不存在虚假记载、误导性陈述或者重大遗 漏。 表决结果：同意三票；反对零票；弃权零票。 表决结果：同意三票；反对零票；弃权零票。 ...

证券代码：300138 证券简称：晨光生物 编号：2023-004 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 投资者关系活动类 别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他 参与单位名称及人 员姓名 参加 2023 年河北辖区上市公司网上集体接待日的投资者 时间 2023 年 5 月 30 日下午 15:00-17:00 地点 全景网"投资者关系互动平台"（https://ir.p5w.net） 上市公司接待人员 1、董事会秘书、财务负责人周静 2、证券事务代表高智超 公司于 2023 年 5 月 30 日通过全景网"投资者关系互 动平台"（https://ir.p5w.net）采用网络远程的方式召开 业绩说明会，公司就投资者在本次说明会中提出的问题进 行了回复，详见全景网本次业绩说明会的交流内容。主要 问题及回复如下： 1、您好，请问公司认为什么时候会扩大中药方面的市 投资者关系活动主 场？ 要内容介绍 您好，中药、保健品是公司第三部发展战略方向，现 阶段主要以研发、投入为主。谢谢关注。 2、建议公司大健康板块可开发含番茄红素和含叶黄素 的矿泉水，或与该领域的龙头比如农夫山泉 ...